Yuen & Partners v. Dbs Bank (Hong Kong) Ltd
Read the full judgment text of HCMP 1609/2020 on BabelCite. This High Court CFI judgment was delivered on 16 October 2020.
1. By originating summons dated 29 September 2020, the plaintiff, which is a firm of solicitors practising in Hong Kong, seeks the following orders against the defendant, which is a corporation carrying on banking business in Hong Kong. The order sought was as follows:
Cited by 3 cases · Cites 3 cases
|
HCMP 1609/2020 [2020] HKCFI 2815 IN THE HIGH COURT OF THE HONG KONG SPECIAL ADMINISTRATIVE REGION COURT OF FIRST INSTANCE MISCELLANEOUS PROCEEDINGS NO 1609 OF 2020 ________________________
________________________
___________________ J U D G M E N T ___________________ 1.By originating summons dated 29 September 2020, the plaintiff, which is a firm of solicitors practising in Hong Kong, seeks the following orders against the defendant, which is a corporation carrying on banking business in Hong Kong. The order sought was as follows:
2.Despite the fact that section 41 of the High Court Ordinance[1] is mentioned in the originating summons, Mr Pang, counsel for the plaintiff, confirms to me at the hearing that this is an application made under the Norwich Pharmacal principles and not under section 41. 3.The plaintiff formerly acted for Promo International Limited (“Promo”) against the holders of the subject accounts in a High Court action. The background can be gleaned from the affirmation of Mr Hau Chi-kit on behalf of the plaintiff as follows:
4.In gist, it appears that the balances in the subject accounts that were subject to an injunction granted by To J in the previous action had apparently been depleted significantly. That injunction was granted until trial. So it would appear that the depletion happened after the trial which took place between 1 August 2017 and 1 September 2017. 5.On 28 February 2018, the trial judge, B Chu J, handed down a judgment in Promo’s favour. Another injunction was granted on 27 April 2018 by B Chu J on that day and continued by Deputy High Court Judge Keith Yeung SC (as he then was) later. So it appears that there was a “gap” between 1 September 2017 and 27 April 2018 when the subject accounts were not covered by any injunction. 6.Promo is now suing the plaintiff in a fresh action. At paragraph 29 of Mr Hau’s affirmation, he said:
7.In the fresh action, it appears that Promo is blaming the plaintiff for the depletion of the accounts, and according to paragraph 18 of the skeleton of Mr Pang:
8.As I said, this application is made under the Norwich Pharmacal jurisprudence. 9.In his helpful skeleton, Mr Pang submitted:
10.As Ma J (as he then was) said A v B[2]:
That judgment by Ma J was, of course, followed in many subsequent cases including recently by Chow J in Leung Yiu Ting v MTR Corporation Limited[3]. 11.In my judgment, alleged wrongdoing or possible wrongdoing by someone is the essence of a Norwich Pharmacal application and order. The plaintiff in such an application seeks the information on the alleged or possible wrongdoing from a third party innocently mixed up in the wrongdoing (and not being a mere witness). And, of course, where the third party is not only an innocent party mixed up in wrongdoing but has actually involved in the wrongdoing, the position is a fortiori. But the essence is that the applicant for the Norwich Pharmacal order is seeking information so that it may or will pursue the wrongdoer to enforce his legal rights. 12.As Mr Pang very frankly and very fairly accepts, this is a rather unusual application for a Norwich Pharmacal order because, as Mr Pang himself again very fairly and frankly accepts at paragraph 25 of his skeleton which I quoted above, the plaintiff is not strictly alleging wrongdoing against any specific party, whether Chow, Chae nor Promo. Rather, it is saying that it is possible that the depletion of funds did not involve any wrongdoing. There may well be innocent explanations for the depletion and actually it is seeking evidence to support that. That is, it is seeking evidence of no wrongdoing, which will vindicate it in the fresh action, and not as a victim of any such alleged or possible wrongdoing (which the applicant has some basis for believing may have occurred) which the applicant is seeking to sue upon with the assistance of the information sought. 13.I note that the Norwich Pharmacal jurisdiction or jurisprudence is supposed to be flexible and is developing all the time (see, for example, Ashworth Hospital Authority v MGN Limited[4]; Rugby Football Union v Consolidated Information Services Limited (formerly Viagogo Limited)[5]; and Leung Yiu Ting[6]). 14.On the other hand, the cases including A v B which I quoted above have cautioned that a Norwich Pharmacal order is a relief of extraordinary nature and is not one to be made lightly. 15.This case is, as I said, unusual, and in my judgment it goes beyond the basis and rationale of a Norwich Pharmacal order. In essence, the plaintiff’s case is that the disclosure should be ordered in the interest of justice and it will save time and costs in the current action between Promo and the plaintiff because depending on what will be disclosed by the defendant bank, if I were to order disclosure, the plaintiff may well accept liability or at least issues may be significantly reduced or limited in the current action. Otherwise, he said the plaintiff would have to prepare the defence to Promo’s action “blind”. 16.But, however, if this is correct, that would mean that where there is any dispute between two parties, X and Y, X can obtain discovery from any third party when the information or document sought is relevant to any issue between X and Y. That third party, of course, can be an innocent party or a fortiori a wrongdoer of some sort himself. But if that third party has relevant information or documents to be disclosed on the existing issue between X and Y (where there must be some sort of wrongdoing being alleged between them), it would not be difficult in most of these cases to say that the third party was caught up or involved in the wrongdoing (although, of course, this is not invariably the case because if the third party is a mere witness, then the Norwich Pharmacal principle does not apply). 17.Ultimately, then the question becomes one of whether it is in the interest of justice to order disclosure from a third party in a dispute between X and Y. That would be opening the floodgates of third-party discovery where the main, if not the only, consideration would be the interest of justice and saving times and costs. I have no doubt that these are important and relevant considerations but they cannot be the sole considerations which, in my judgment, is what Mr Pang’s submission boils down to. 18.For the reasons above, I do not believe that this is a case where a disclosure order under the Norwich Pharmacal principles should be made despite the very helpful and eloquent submissions made by Mr Pang in support of the plaintiff’s application. In particular, while he said that there was in fact an element of wrongdoing here but, of course, the wrongdoing he refers to is the allegation of wrongdoing by Promo against the plaintiff which, as I say, would always exist in some way between two parties when third-party discovery is being sought, and I do not believe that this is a kind of wrongdoing which is relevant to a Norwich Pharmacal application. 19.For these reasons, I dismiss the application with an order nisi that there be no order as to costs, and I thank Mr Pang for his very helpful submissions.
Mr Ronald Pang, instructed by Yuen & Partners, for the plaintiff The defendant was not represented and did not appear | |||||||||||||||||||||||||
Cases cited in this judgment